BioToxTech Co

BioToxTech Co DSCR

The Debt Service Coverage Ratio (DSCR) of BioToxTech Co (086040.KQ) as of Oct 20, 2026 is 0.59. In the previous year, Debt Service Coverage Ratio (DSCR) was -0.18 — a change of -419.03% (higher).

DSCR

0.59

YoY

-419.03%

Last updated:

Debt Service Coverage Ratio (DSCR) of BioToxTech Co is 2025 0.59 . Debt Service Coverage Ratio (DSCR) of BioToxTech Co was 2024 -0.18 . It decreases by -419.03% higher compared to the previous year.

The BioToxTech Co DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2018
0.18 KRW
Jan 1, 2019
0.09 KRW
Jan 1, 2020
0.37 KRW
Jan 1, 2021
0.28 KRW
Jan 1, 2022
-0.04 KRW
Jan 1, 2023
-0.37 KRW
Jan 1, 2024
-0.18 KRW
Jan 1, 2025
0.59 KRW
The BioToxTech Co DSCR history
YEARDSCRYoY
0.59-419.03%
-0.18-49.87%
-0.37+871.69%
-0.04-113.41%
0.28-23.48%
0.37+325.80%
0.09-52.41%
0.18-53.63%
0.39+0.55%
0.39-792.32%
-0.06-93.09%
-0.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Debt Service Coverage Ratio (DSCR) of BioToxTech Co is 0.59 in 2025.

Debt Service Coverage Ratio (DSCR) of BioToxTech Co changed from -0.18 to 0.59, representing a -419.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioToxTech Co

All Key Metrics — BioToxTech Co